Non-dilutive finance

The alliance with GenesisCare has the potential to be very profitable for Noxopharm.

GenesisCare has been using NOX66 on a compassionate basis for some time, according to the alliance announcement, with promising results. My view is that Noxopharm would not have committed to supply NOX66 to GenesisCare unless it was able to charge a reasonable fee for its drug, therefore this alliance is highly likely to provide a source of non-dilutive funds for the Company.

GenesisCare is aggressively expanding in Europe and the US and will be able to tell prospective patients that NOX66 significantly improves the performance of both external and internal radiation. Demand for treatment should be high, potentially leading to substantial income for Noxopharm.